What is Monopar Therapeutics's EPS (diluted)?

Monopar Therapeutics (MNPR) reported EPS (diluted) of -$0.19 in Q1 2022.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Monopar Therapeutics MNPR EPS (Diluted)

Discontinued — last reported Q1 '22

EPS (Diluted) at other companies

Bristol-Myers SquibbBMY

$1.31+9.2%

Eli LillyLLY

$8.26+170%

Bausch Health CompaniesBHC

-$3.82-2,287%

Ultragenyx PharmaceuticalRARE

-$1.84-17.2%

Prime MedicinePRME

-$0.28+30.0%

Wave Life SciencesWVE

-$0.13+55.2%

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasicAndDiluted.

The official record: Monopar Therapeutics’s 10-Q, filed May 12, 2022, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's EPS (diluted)?: Monopar Therapeutics (MNPR) reported EPS (diluted) of -$0.19 in Q1 2022.
What does EPS (diluted) mean?: Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.